Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Susan Wroblewski"'
Autor:
Stefan Knop, Maria-Victoria Mateos, Meletios A. Dimopoulos, Kenshi Suzuki, Andrzej Jakubowiak, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Ganna Usenko, Ludek Pour, Mark Cook, Sebastian Grosicki, Andre Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova, Sung-Soo Yoon, Genadi Losava, Tomoaki Fujisaki, Mamta Garg, Jianping Wang, Susan Wroblewski, Anupa Kudva, Katharine S. Gries, John Fastenau, Jesus San-Miguel, Michele Cavo
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-14 (2021)
Abstract Background In the phase III ALCYONE trial, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) significantly improved overall response rate and progression-free status compared with VMP alone in transplant-ineligible patients with newly
Externí odkaz:
https://doaj.org/article/b999c61f13244d59a68cdf925de95954
Autor:
Maria-Victoria Mateos, Sophie Rigaudeau, Supratik Basu, Ivan Spicka, Rik Schots, Tomasz Wrobel, Gordon Cook, Meral Beksac, Katharine S Gries, Anupa Kudva, Brenda Tromp, Rian Van Rampelbergh, Huiling Pei, Susan Wroblewski, Robin Carson, Maria Delioukina, Darrell White
Introduction Two phase 3 studies demonstrated superior efficacy of intravenous daratumumab (DARA IV) plus bortezomib/melphalan/prednisone (ALCYONE) or lenalidomide/dexamethasone (Rd; MAIA) versus standard-of-care regimens for transplant-ineligible ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bacbd973ef3583b7c1d5c40ab6d1735b
https://hdl.handle.net/20.500.14017/1d6168cb-e413-4fc4-a468-ac4c8d8875d8
https://hdl.handle.net/20.500.14017/1d6168cb-e413-4fc4-a468-ac4c8d8875d8
Autor:
Marijo Bilusic, Nicole J. Toney, Renee N. Donahue, Susan Wroblewski, Matthew Zibelman, Pooja Ghatalia, Eric A. Ross, Fatima Karzai, Ravi A. Madan, William L. Dahut, James L. Gulley, Jeffrey Schlom, Elizabeth R. Plimack, Daniel M. Geynisman
Publikováno v:
Prostate Cancer and Prostatic Diseases. 25:735-740
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ddb4924ee6ccebaadf5840d3fe9458c5
https://doi.org/10.1038/s41391-022-00492-y
https://doi.org/10.1038/s41391-022-00492-y
Autor:
Linda Sciuto, Yves Pommier, Cody J. Peer, William D. Figg, Thomas P. C. Dorlo, Lisa M. Cordes, Anish Thomas, Susan Wroblewski, Alwin D. R. Huitema, Keith T. Schmidt, Ravi A. Madan
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose NLG207 (formerly CRLX101) is a nanoparticle–drug conjugate (NDC) of the potent topoisomerase I inhibitor, camptothecin (CPT). The present study sought to characterize the complex pharmacokinetics (PK) of NLG207 and better describe CPT relea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa45f81de46ecd74a5d93ae1ea7af06b
http://europepmc.org/articles/PMC7515962
http://europepmc.org/articles/PMC7515962
Autor:
Marijo, Bilusic, Nicole J, Toney, Renee N, Donahue, Susan, Wroblewski, Matthew, Zibelman, Pooja, Ghatalia, Eric A, Ross, Fatima, Karzai, Ravi A, Madan, William L, Dahut, James L, Gulley, Jeffrey, Schlom, Elizabeth R, Plimack, Daniel M, Geynisman
Publikováno v:
Prostate cancer and prostatic diseases. 25(4)
Metformin may have anticancer effects that are independent of its hypoglycemic effects. Retrospective studies have shown that metformin use is associated with decreased incidence of prostate cancer and prostate cancer-specific mortality. Preclinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1cc79dd2018ad67d798b1a18332bff32
https://pubmed.ncbi.nlm.nih.gov/35079115
https://pubmed.ncbi.nlm.nih.gov/35079115
Autor:
Katharine S. Gries, Philip Campbell, Genadi Losava, Mark J. Cook, Jesús F. San-Miguel, Tatiana Shelekhova, Anupa Kudva, Chantal Doyen, Maria-Victoria Mateos, Meletios A. Dimopoulos, Anna Marina Liberati, Stefan Knop, John Fastenau, Michele Cavo, Ludek Pour, Susan Wroblewski, Kenshi Suzuki, Ganna Usenko, Andrzej Jakubowiak, Paulo Sérgio Lucio, Sung-Soo Yoon, Zsolt Nagy, Jianping Wang, Mamta Garg, Sebastian Grosicki, Tomoaki Fujisaki, Andre Crepaldi
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-14 (2021)
BMC cancer, Vol. 21, no. 1, p. 659 [1-14] (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-14 (2021)
BMC cancer, Vol. 21, no. 1, p. 659 [1-14] (2021)
Background In the phase III ALCYONE trial, daratumumab plus bortezomib/melphalan/prednisone (D-VMP) significantly improved overall response rate and progression-free status compared with VMP alone in transplant-ineligible patients with newly diagnose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd6193d8b5bcdab6d3caaafa2cb6ea68
http://hdl.handle.net/11585/867411
http://hdl.handle.net/11585/867411
Autor:
Keith T Schmidt, Fatima Karzai, Marijo Bilusic, Lisa M Cordes, Cindy H Chau, Cody J Peer, Susan Wroblewski, Alwin D R Huitema, Jan H M Schellens, James L Gulley, William L Dahut, William D Figg, Ravi A Madan
Publikováno v:
Oncologist
Background Despite the clinical efficacy of enzalutamide monotherapy in patients with advanced prostate cancer, therapeutic resistance and disease progression are inevitable. We proposed a study to evaluate NLG207, a nanoparticle-drug conjugate (NDC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8debfa4e974afd9b062b054c3873eb17
https://doi.org/10.1093/oncolo/oyac100
https://doi.org/10.1093/oncolo/oyac100
Autor:
William D. Figg, Ravi A. Madan, Keith T. Schmidt, Jan H.M. Schellens, Alwin D. R. Huitema, Monique Williams, Susan Wroblewski, Cody J. Peer
Publikováno v:
J Pharm Biomed Anal
Camptothecin (CPT), a potent inhibitor of topoisomerase I and HIF-1α, failed to demonstrate utility as an anti-cancer agent in early clinical trial investigations, primarily due to limited clinical activity and significant toxicity attributable to u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b19c198ca6e7c0af08bc2e5bea7631e4
https://europepmc.org/articles/PMC7068816/
https://europepmc.org/articles/PMC7068816/
Autor:
Weijun Fu, Jae Hoon Lee, Jian Hou, Honghui Huang, Paula Rodriguez-Otero, Yang Song, Ming Qi, Robin Carson, Yunan Li, Meletios A. Dimopoulos, Kihyun Kim, Jianping Wang, Chor S. Chim, Bin Jia, Jianxiang Wang, Wenyu Liu, Tomoaki Fujisaki, Renyi Zhang, Je-Jung Lee, Jie Jin, Yafei Wang, Susan Wroblewski, Gang An, Wei Li, Soo Mee Bang, Zhen Cai, Xue Yang
Publikováno v:
Blood. 138:1661-1661
Introduction: Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with a direct on-tumor and immunomodulatory mechanism of action. In the global phase 3 ALCYONE trial, the addition of daratumumab to bortezomib, melphalan, and prednisone (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::187e860c732939114f3e77ae36d81ba7
https://doi.org/10.1182/blood-2021-146974
https://doi.org/10.1182/blood-2021-146974
Autor:
Jae Hoon Lee, Jianxiang Wang, Weijun Fu, Paula Rodriguez-Otero, Yafei Wang, Soo Mee Bang, Yang Song, Bin Jia, Meletios A. Dimopoulos, Honghui Huang, Wenyu Liu, Jian Hou, Anna Marina Liberati, Chor S. Chim, Renyi Zhang, Je-Jung Lee, Kihyun Kim, Gang An, Robin Carson, Ming Qi, Yunan Li, Jie Jin, Susan Wroblewski, Wei Li, Jianping Wang, Hiroyuki Takamatsu, Zhen Cai, Xue Yang
Publikováno v:
Blood. 138:1648-1648
Introduction: Daratumumab is a human IgGκ monoclonal antibody that targets CD38 with a direct on-tumor and immunomodulatory mechanism of action. In the primary analysis (median follow-up, 16.5 months) of the global phase 3 ALCYONE trial, daratumumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cd31f8902d67f053e118b6fb56747c6f
https://doi.org/10.1182/blood-2021-148937
https://doi.org/10.1182/blood-2021-148937